Updates from the Exchange

Post written by Margaret Gaw, Stanback Fellow with FHI 360 A new report by the British Pregnancy Advisory Service (BPAS), researchers at...

The COVID-19 pandemic has created acute disruptions to public health supply chains, revealing underlying vulnerabilities in the global...

The drospirenone progestin-only pill (POP) is an estrogen-free daily oral contraceptive that received regulatory approval in both the US...

The United States Food and Drug Administration (FDA) approved Mirena® for an additional year of duration, extending its indication for up...

Sparked by conversations from the 2019 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)...

The U.S. Food and Drug Administration has issued approval for a new type of birth control gel.

The Global Health Network has announced that the Trials Methodology Research Partnership (TMRP) has made available funds for small...

A woman’s menstrual cycle – though critical for conceiving life, can also be painful, messy, and downright uncomfortable. And, women who...

Amphora, an investigational Multipurpose Vaginal pH Regulator (MVP-RTM), shows promise for the United States Food and Drug Administration...

On December 11, 2019, Amneal Pharmaceuticals received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug...

Researchers from the Georgia Institute of Technology, University of Michigan and FHI 360, are attempting to expand the number of user...

Researchers may have found a novel delivery mechanism that will allow an extended release birth control pill to provide one month of...